Tweets from Hootsuite

Feinberg: What if some signal for stochastic var related to common SNPs? And why in the context of evolution? #AMP2017

10:47am November 16th 2017 via Hootsuite

Feinberg: Like quantum mechanics where stochastic variation plays a fundamental role. '10 PNAS https://t.co/9xViWAMn9Q #AMP2017

10:46am November 16th 2017 via Hootsuite

Feinberg: While visiting Big Ben in London, '09: shows difference between Newton's grave (elaborate) and Darwin's grave (simple). #AMP2017

10:44am November 16th 2017 via Hootsuite

Feinberg: Meeting 'missing heritability in common disease' NIH conference, he had only 7 minutes! Battle over comment in publ. #AMP2017

10:39am November 16th 2017 via Hootsuite

Feinberg: Clustering from '09 ref: stochastic var in DNAm in isogenic mice: is there a conserved driver for epigenetic var? #AMP2017

10:38am November 16th 2017 via Hootsuite

Sabath (Univ WA) '09 from Feinberg's group Nature Gen https://t.co/Xm2qd92XCw that looked at 4.6M CpG's genomewide via method CHARM #AMP2017

10:36am November 16th 2017 via Hootsuite

What an interesting way to look at tissue-specific developmental changes. Daniel Sabath #AMP2017 https://t.co/Jd4JkNdUzv

10:30am November 16th 2017 via Hootsuite

Harris con't:Sarcomas likely have oncogenic fusion. In 9pts, had enough smaple to send for RNA seq to look for fusions #AMP2017

9:58am November 16th 2017 via Hootsuite

Q: Comment on employing other genomic technology (i.e. RNA) Harris: If enough sample, aCGH. If CNA led to inc expression, then IHC #AMP2017

9:57am November 16th 2017 via Hootsuite

Q: What was TAT for iCat? Harris: On the order of months. Realistically: 4 weeks. Sending samples, review, sending out... #AMP2017

9:54am November 16th 2017 via Hootsuite

Harris: Unanswered Q's: impact of receiving matched Rx on outcome; factors influencing receipt of matched Rx #AMP2017

9:52am November 16th 2017 via Hootsuite

Harris: Also ID'd 11 pts with potential germline variants for cancer risk, even though germline samples were not provided. #AMP2017

9:51am November 16th 2017 via Hootsuite

Harris: Showed all the tissue types from this '16 JAMA Oncol paper https://t.co/td4Vmu6kIb #AMP2017

9:42am November 16th 2017 via Hootsuite

Harris: Called iCat, samples sent to Dana Farber, molecular testing, expert panel review, letter of treatment back to host inst. #AMP2017

9:40am November 16th 2017 via Hootsuite

Harris: Looked at feasibility of Precision Med for pediatric recurrent, refractory, or high risk solid tumors #AMP2017

9:39am November 16th 2017 via Hootsuite

Harris: Rare, few sequence alterations, small biopsies (from small people), few trials and drugs #AMP2017

9:37am November 16th 2017 via Hootsuite

Harris: Starts with ACS Siegel 2017 chart of '17 new cancer cases. Ref: https://t.co/BIF3wAVxEw Points out rarity of pediatric ca #AMP2017

9:36am November 16th 2017 via Hootsuite

Marian Harris (Boston Childrens Hosp) Molecular Diagnostics in Multi-Institutional Trials: A Pathologist's Perspective #AMP2017

9:35am November 16th 2017 via Hootsuite

Williams: Acknowledges pts, physicians, NCI clinical trials network, a core group of about 150 and 18 working groups. #AMP2017

9:33am November 16th 2017 via Hootsuite

Williams: Not a screen specifically for MATCH, but if they have one of the rare var's, will then enroll. #AMP2017

9:30am November 16th 2017 via Hootsuite

Williams: 6K pts enrolled in less than 2y; but a few arms are still open. FMI, MSKCC, Caris are up and running, screening routinely #AMP2017

9:30am November 16th 2017 via Hootsuite

Williams: Problem cases no pathology report, or no tumor in sample. One arm - no variant found yet to put on a protocol #AMP2017

9:28am November 16th 2017 via Hootsuite

Williams: 60% of samples were considered rare tumor types. Goal of TAT was 14d; currently 16d. 20% of cases 'were problem ones'. #AMP2017

9:27am November 16th 2017 via Hootsuite

Williams: Details of this validation published JMD Mar '17 https://t.co/DkM2Rr6rK4 #AMP2017

9:26am November 16th 2017 via Hootsuite

Williams: Looked at cross user, instrument, lab, and day: 'well above 95%'. Able to get 5560 of 5962 samples. 93% vs 80% common. #AMP2017

9:25am November 16th 2017 via Hootsuite

Williams:Showed one lab (MGH) with CNV at only 80% sens. Turned out sample was 3.7 copies, when threshold was 5 #AMP2017

9:23am November 16th 2017 via Hootsuite

Williams: For perf testing: as many different types as they could. 186 samples, 15 tissue types for sensitivity study #AMP2017

9:21am November 16th 2017 via Hootsuite

Williams: Feasibility 'turned out phenomenal'; assay performed 'extremely well in this blinded test'. Harmonized, locked SOPs #AMP2017

9:20am November 16th 2017 via Hootsuite

Williams: Run under FDA's 'Abbreviated IDE' - non-significant risk, updated clinical trial binders/docs, version SOP, site audits #AMP2017

9:19am November 16th 2017 via Hootsuite

Williams: Used Oncomine v1, 143 genes, 4066 annotated var's, RFP selected the four initial labs. #AMP2017

9:17am November 16th 2017 via Hootsuite

Williams: Biopsy sent to MDACC, archived and PTEN IHC and NA extracted. Sent to 4 lab network (20ng FFPE DNA/10ng FFPE RNA). #AMP2017

9:15am November 16th 2017 via Hootsuite

Williams: Example BRAF V600E melanoma response to BRAFi or BRAFi + MEKi. Open to solid tumors, lymphomas, melanoma, rare tumors #AMP2017

9:11am November 16th 2017 via Hootsuite